Table 5.
Treatment-related death (TRD) of patients with standard-risk childhood acute lymphoblastic leukemia (ALL) in complete remission (CR) in the ALL-Moscow–Berlin 2002 trial by randomization arm
| Arm ASP-5000 | Arm ASP-10000 | P Fisher | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| TRD in CR | 9 | 100 | 23 | 100 | 0.029 |
| Time of death | |||||
| Day of therapy, median [interquartile range] | 158 [116–163] | 220 [100–264.75] | 0.213 | ||
| Consolidation I | 4 | 44.4 | 8 | 34.8 | 0.696 |
| Consolidation II | 3 | 33.3 | 1 | 4.3 | 0.057 |
| Consolidation III | 1 | 11.1 | 8 | 34.8 | 0.383 |
| Maintenance therapy | 1 | 11.1 | 6 | 26.1 | 0.640 |
TRD in CR occurred significantly less frequently in arm ASP-5000 (9/334 patients) than arm ASP-10000 (23/354 patients). In arm ASP-10000, more than 60% of TRD were seen late (in consolidation III and maintenance therapy), whereas about 80% of TRD in arm ASP-5000 occurred early (during consolidation I and II)
Statistical significant р values are in bold